Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Donald Diamond
Beckman Research Institute/city of Hope, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Helocyte Biosciences
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Helocyte Biosciences is a company focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious diseases, in particular, cytomegalorvirus or “CMV.” Dr. Diamond is Principal Investigator on the funded research grant, “CMV PepVax to Protect HCT Recipients from Cytomegalovirus Infection,” the aims of which are a multi-center evaluation of CMVPepVax in matched unrelated donors and a multi-center evaluation of protective function of CMVPepVax in high risk unrelated donors. Given the similarities between the company’s product development and the aims of the grant, the interest was determined to be related.
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
Hematopoietic stem cell transplantation (HCT) is one of the most successful cancer therapeutic approaches, yet side effects that include infectious complications limit its effectiveness. Among the infectious complications that are most severe are herpes virus infections including cytomegalovirus (CMV). Building upon our successful safety trial in healthy volunteers of the CMV peptide therapeutic called CMVPepVax, we will expand the investigation by conducting 2 consecutive randomized, placebo-controlled Phase 2 trials whose outcome will be a definitive answer whether our approach is effective in at-risk patients and spares them toxicity of anti- viral chemotherapy.
Filed on November 03, 2016.
Tell us what you know about Donald Diamond's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.